Since being acquired by Bayer for $1.5 billion last year, Vividion Therapeutics remains bullish in its hunt for undruggable targets for cancer. The Californian biotech has partnered with Tavros ...

DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Tavros Therapeutics, Inc., a precision oncology platform company, today announced that the Company has achieved two milestone payments in its ...

DURHAM – The precision oncology startup Tavros Therapeutics has closed $7.5 million in a second seed funding round, the company announced today. Existing investor Piedmont Capital Investments co-led ...

NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply Tavros’ ...

If construction loans are what make projects real, Tavros and Charney’s two-tower Gowanus development is about to get off the ground. Nicholas Silvers and Sam Charney’s companies nabbed two ...

Charney Companies, a fully integrated real-estate development, construction, brokerage, and management company, and Tavros, a real-estate investment management and development company, have announced ...

SAN DIEGO & BERLIN & DURHAM, N.C.--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally ...

RESEARCH TRIANGLE PARK – Durham-based biotechnology startup Tavros Therapeutics will partner with Bayer AG subsidiary Vividion Therapeutics to find new targets and treatments for cancer. The two ...

NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply ...